BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today preclinical results from a combination study of seliciclib, an orally-available cyclin dependent kinase (CDK) inhibitor, with epidermal growth factor receptor (EGFR) inhibitor erlotinib (Tarceva®). The study demonstrated that the drugs act synergistically in suppressing tumor growth in models of non-small cell lung cancer (NSCLC). The data, presented as a poster (#4003) at the Annual Meeting of the American Association for Cancer Research (AACR) in Los Angeles, is part of the company’s broad program to assess the potential of seliciclib. Currently, seliciclib is being evaluated in a Phase II randomized double-blinded clinical trial as a single agent in NSCLC.
